SHELTON, CT / ACCESSWIRE / October 3, 2019 / NanoViricides, Inc., (NYSE American:NNVC) (the “Company”), a leader in developing novel nanomedicines to treat viral diseases, based on the nanoviricides® platform, announces that Anil R. Diwan, PhD, President and Executive Chairman, was interviewed by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London.
The Company recently announced that its first clinical drug candidate, NV-HHV-101, for the treatment of the Shingles virus (aka VZV), is on track with required preclinical GLP Safety and Toxicology studies moving towards human clinical trials. The Company has reported that NV-HHV-101 has been found to be safe and well tolerated in the clinical observation portion of the GLP Safety/Toxicology study of NV-HHV-101 as a dermal treatment. The in-life stage of the first part of the GLP studies is complete, allowing assessment of clinical observations. During the interview, Dr. Diwan discussed this major milestone and while doing so, also described the potential market for the several therapies the Company has in its pipeline. The HerpeCide™ program indications themselves represent a significant market-size opportunity of over $3 Billion.
Responding to Ms. Corrado’s questions, Dr. Diwan outlined the potentially life-changing impact of the Company’s antiviral therapies and the significance of addressing unmet medical needs and underserved populations affected by the viral diseases that the Company is targeting at present. The Company’s current programs target a potential market opportunity of over $20 Billion.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, shingles and chickenpox, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company’s drug candidates are based on licensed patents and technologies of TheraCour Pharma, Inc., a pioneer in nanomedicines based on polymeric micelle technologies originally developed by Dr. Diwan and colleagues. A license for VZV field of application is currently being negotiated; a memorandum of understanding regarding the terms of this license has been agreed upon between the parties. This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. (FDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medicines Agency.)
SOURCE: NanoViricides, Inc.
View source version on accesswire.com: